Ionis Pharmaceuticals, Inc. Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses (Deprecated 2013-01-31)
Ionis Pharmaceuticals, Inc. (IONS) had Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses (Deprecated 2013-01-31) of $744.00 thousand as of 2013-06-30, per its 10-Q filed 2013-08-06.
Discontinued › Notes › Investments
us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2 · last filed 2013-08-06
- 2013-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses (Deprecated 2013-01-31) $744.00K.
- 2013-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses (Deprecated 2013-01-31) -$248.00K.
- 2012-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses (Deprecated 2013-01-31) -$185.00K.
- 2012-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses (Deprecated 2013-01-31) -$130.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses (Deprecated 2013-01-31) |
|---|---|
| 2013-06-30 | $744.00K 10-Q · filed 2013-08-06 |
| 2013-03-31 | -$248.00K 10-Q · filed 2013-05-07 |
| 2012-12-31 | -$185.00K 10-K · filed 2013-02-28 |
| 2012-09-30 | -$130.00K 10-Q · filed 2012-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |